KalVista Pharmaceuticals Income Statement (2014-2025) | KALV

Income Statement Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jul2016 Oct2016 Jan2017 Apr2017 Jul2017 Oct2017 Jan2018 Apr2018 Jul2018 Oct2018 Jan2019 Apr2019 Jul2019 Oct2019 Jan2020 Apr2020 Jul2020 Oct2020 Jan2021 Apr2021 Jul2021 Oct2021 Jan2022 Apr2022 Jul2022 Oct2022 Jan2023 Apr2023 Jul2023 Oct2023 Jan2024 Apr2024 Jul2024 Oct2024 Dec2024 Apr2025 Jul2025
Revenue & cost
Revenue (Quarter)
11.00M57.00M
Cost of Revenue (Quarter)
0.59M
Gross Profit (Quarter)
56.41M
Operating items
Research & Development (Quarter)
9.15M9.10M11.88M13.67M17.55M19.74M19.21M18.19M18.08M20.06M23.95M19.31M19.09M22.52M25.25M26.61M16.61M15.89M15.16M
Selling, General & Administrative (Quarter)
3.63M3.56M6.17M5.85M6.06M6.95M7.60M8.13M7.81M6.88M7.78M9.79M10.66M10.63M23.21M17.60M29.20M39.14M44.68M
Other Operating Expenses (Quarter)
0.59M
Operating Expenses (Quarter)
12.78M12.66M18.04M19.52M23.60M26.68M26.81M26.32M25.88M26.95M31.73M29.09M29.75M33.15M48.45M44.22M45.81M55.03M60.44M
Operating Income (Quarter)
-12.78M-12.66M-18.04M-19.52M-23.60M-26.68M-26.81M-26.32M-25.88M-26.95M-31.73M-29.09M-29.75M-33.15M-48.45M-44.22M-45.81M-55.03M-59.01M
EBIT (Quarter)
-12.78M-12.66M-18.04M-19.52M-23.60M-26.68M-26.81M-26.32M-25.88M-26.95M-31.73M-29.09M-29.75M-33.15M-48.45M-44.22M-45.81M-55.03M-59.01M
Non-operating items
Interest & Investment Income (Quarter)
0.19M0.14M0.31M0.27M0.29M0.26M0.27M0.24M0.45M0.73M0.81M0.92M0.78M0.68M1.51M1.69M1.36M1.99M1.85M
Other Non Operating Income (Quarter)
2.19M0.30M2.64M-0.05M-0.28M4.16M-12.82M-0.52M3.49M4.31M-11.26M2.40M-1.30M1.12M-0.14M1.57M2.12M5.21M0.82M
Non Operating Income (Quarter)
2.35M2.17M2.64M3.18M3.94M4.16M3.44M3.55M3.63M4.31M6.61M2.40M2.10M4.12M-0.23M1.57M2.12M-1.18M0.82M
Net income details
EBT (Quarter)
-12.59M-12.52M-17.73M-19.24M-23.31M-26.43M-26.54M-26.07M-25.43M-26.21M-30.92M-28.17M-28.97M-29.03M29.33M-40.44M-44.45M38.56M-57.94M
Tax Provisions (Quarter)
-0.85M2.20M
Profit After Tax (Quarter)
-10.43M-10.05M-14.96M-16.11M-19.65M-22.47M-24.11M-23.04M-22.26M-21.30M-26.30M-25.32M-27.65M-29.03M-44.65M-40.44M-42.27M-52.23M-60.10M
Income from Continuing Operations (Quarter)
-12.59M-12.52M-17.73M-19.24M-23.31M-26.43M-26.54M-26.07M-25.43M-26.21M-30.92M-28.17M-28.97M-29.03M29.33M-40.44M-44.45M39.41M-60.14M
Consolidated Net Income (Quarter)
-12.59M-12.52M-17.73M-19.24M-23.31M-26.43M-26.54M-26.07M-25.43M-26.21M-30.92M-28.17M-28.97M-29.03M29.33M-40.44M-44.45M39.41M-60.14M
Income towards Parent Company (Quarter)
-12.59M-12.52M-17.73M-19.24M-23.31M-26.43M-26.54M-26.07M-25.43M-26.21M-30.92M-28.17M-28.97M-29.03M29.33M-40.44M-44.45M39.41M-60.14M
Net Income towards Common Stockholders (Quarter)
-12.59M-12.52M-17.73M-19.24M-23.31M-26.43M-26.54M-26.07M-25.43M-26.21M-30.92M-28.17M-28.97M-29.03M29.33M-40.44M-44.45M39.41M-60.14M
Additional items
EPS (Basic) (Quarter)
-0.58-0.56-0.67-0.66-0.80-0.92-0.98-0.94-0.90-0.75-0.75-0.74-0.80-0.84-1.07-0.87-0.91-0.99-1.12
EPS (Weighted Average and Diluted) (Quarter)
-0.93-0.66-0.80-0.92-0.98-0.94-0.90-0.75-0.75-0.74-0.80-0.84-1.07-0.87-0.91-0.99-1.12
Shares Outstanding (Weighted Average) (Quarter)
17.88M17.96M19.09M24.43M24.44M24.45M24.47M24.56M24.58M28.28M27.89M34.41M34.57M34.72M36.79M46.23M46.46M49.43M49.65M53.50M
Shares Outstanding (Diluted Average) (Quarter)
19.09M24.43M24.43M24.45M24.47M24.56M24.60M28.28M27.89M34.41M34.57M34.72M36.79M46.23M46.70M49.65M53.50M
EBITDA (Quarter)
-10.76M-9.36M-15.12M-16.17M-19.88M-23.09M-25.64M-23.33M-23.43M-19.52M-25.82M-25.15M-28.22M-28.86M-44.84M-39.82M-42.10M-55.23M-61.27M
Interest Expenses (Quarter)
3.52M
Tax Rate (Quarter)
-2.20%-3.80%